Entering text into the input field will update the search result below

InSite Vision completes BromSite NDA filing

Jun. 11, 2015 9:24 AM ETInSite Vision, Inc. (INSV) StockINSVBy: Douglas W. House, SA News Editor
  • InSite Vision (OTCQB:INSV) completes the filing of its New Drug Application (NDA) for BromSite for the treatment of inflammation and prevention of pain in cataract surgery. The completion of the NDA filing satisfies InSite's obligation under its merger agreement with QLT. The transaction is expected to close in Q3.
  • BromSite is a low dose (0.075%) bromfenac ophthalmic solution. Bromfenac is a non-steroidal anti-inflammatory drug (NSAID).

Recommended For You

More Trending News

Related Stocks

SymbolLast Price% Chg
INSV--
InSite Vision, Inc.